“…Overall, successful device deployment is achieved in 85% to 100% of cases, and periprocedural mortality ranges from 0% to 14%, falling within or below elective surgery mortality rates of 5% to 20%. 68,[75][76][77][78][79][80][81][82][83][84][85][86][87][88][89][90] As expected, outcomes have improved over time with accumulated technical expertise, use of commercially manufactured devices, and improved patient selection criteria. The recently published collective experiences of the EUROSTAR and United Kingdom Thoracic Endograft registries, the largest series to date (nϭ249), demonstrate successful deployment in 87% of cases, 30-day mortality of 5% for elective cases, and paraplegia and endoleak rates of 4%.…”